Farxiga (Dapagliflozin) FDA Approval History

Original Approval: Type 2 Diabetes (January 2014)

The FDA approved dapagliflozin 5 mg and 10 mg tablets on January 8, 2014, making Farxiga the second SGLT2 inhibitor to reach the U.S. market after canagliflozin (Invokana), which had been approved in March 2013 [1]. The approval was based on a clinical development program of more than 9,000 patients across 16 placebo-controlled and active-comparator trials.

In the key phase III studies, dapagliflozin 10 mg reduced HbA1c by 0.5% to 0.7% compared with placebo at 24 weeks, with a concurrent mean weight loss of approximately 2 to 3 kg [2]. The FDA required AstraZeneca to conduct five post-marketing studies, including a cardiovascular outcomes trial that would eventually become the DECLARE-TIMI 58 study. At the time of approval, the label carried precautions for genital mycotic infections, urinary tract infections, and hypotension. A note about a numerical imbalance in bladder cancer cases from pooled clinical trial data was also included, though the FDA concluded the signal did not establish a causal relationship [1].

The European Medicines Agency (EMA) had actually approved dapagliflozin first, in November 2012, making the U.S. approval roughly 14 months behind Europe. The FDA had initially issued a complete response letter in January 2012, requesting additional data on breast and bladder cancer signals observed during clinical trials [3].

DECLARE-TIMI 58: The Cardiovascular Outcomes Trial (2019)

DECLARE-TIMI 58 enrolled 17,160 patients with type 2 diabetes who either had established atherosclerotic cardiovascular disease or multiple risk factors [4]. The trial met its primary safety endpoint but produced a more nuanced efficacy picture than many expected.

Dapagliflozin did not significantly reduce major adverse cardiovascular events (MACE) compared with placebo (8.8% vs. 9.4%; HR 0.93 to 95% CI 0.84 to 1.03; P=0.17) [4]. It did, however, significantly reduce the co-primary endpoint of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; HR 0.83 to 95% CI 0.73 to 0.95; P=0.005). This split result shaped the regulatory path forward. Rather than pursue a broad cardiovascular risk-reduction claim for diabetes patients, AstraZeneca pivoted toward dedicated heart failure and kidney disease trials. That pivot paid off.

The DECLARE results also confirmed the renal protective signal seen in earlier SGLT2 inhibitor trials, with a 47% relative risk reduction in a composite renal endpoint [4]. The trial's principal investigator, Dr. Stephen Wiviott of Brigham and Women's Hospital, stated: "The renal and heart-failure benefits we observed suggested that dapagliflozin's effects go well beyond glucose lowering" [4].

Heart Failure Indication: DAPA-HF (May 2020)

On May 5, 2020, the FDA approved Farxiga for the treatment of heart failure with reduced ejection fraction (HFrEF, NYHA class II-IV), regardless of the presence of type 2 diabetes [5]. This was a landmark decision. Dapagliflozin became the first SGLT2 inhibitor approved for heart failure in patients without diabetes.

The approval rested on DAPA-HF, a trial of 4,744 patients with LVEF ≤40% and elevated NT-proBNP levels [5]. Over a median follow-up of 18.2 months, dapagliflozin 10 mg reduced the composite of worsening heart failure events or cardiovascular death by 26% compared with placebo (HR 0.74 to 95% CI 0.65 to 0.85; P<0.001) [5]. The number needed to treat (NNT) to prevent one primary event was 21 over the trial period.

The benefit was consistent across patients with and without diabetes, a finding that surprised some cardiologists given the drug's glucose-lowering mechanism. Dr. John McMurray of the University of Glasgow, the trial's lead investigator, noted: "DAPA-HF shows that SGLT2 inhibitors are, in truth, heart and kidney drugs that also happen to lower glucose" [5].

The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores also improved significantly with dapagliflozin, reflecting better symptom burden and quality of life [6]. The FDA review was completed in just six months, reflecting the strength of the data and the unmet need in heart failure treatment.

Chronic Kidney Disease Indication: DAPA-CKD (April 2021)

The FDA expanded the Farxiga label on April 22, 2021, to include the treatment of chronic kidney disease (CKD) at risk of progression, again irrespective of diabetes status [7]. DAPA-CKD enrolled 4,304 patients with an eGFR of 25 to 75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5 to 000 mg/g [8].

The trial was stopped early for overwhelming efficacy at a planned interim analysis. The primary composite outcome (sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death) occurred in 9.2% of the dapagliflozin group versus 14.5% of the placebo group (HR 0.61 to 95% CI 0.51 to 0.72; P<0.001) [8]. That 39% relative risk reduction held across patients with and without diabetes, and across a range of baseline eGFR values.

The CKD approval made dapagliflozin the first SGLT2 inhibitor with three distinct indications. AstraZeneca's regulatory strategy of pursuing dedicated outcome trials for each condition, rather than relying solely on subgroup analyses from DECLARE, became a case study in SGLT2 inhibitor development [7].

Broadened Heart Failure Label: Full EF Spectrum (August 2023)

In August 2023, the FDA updated the Farxiga label to cover heart failure across the full ejection-fraction spectrum, removing the restriction to HFrEF [9]. This update followed the results of DELIVER, a trial of 6,263 patients with heart failure and LVEF >40% (HFmrEF and HFpEF) [10].

DELIVER demonstrated a statistically significant 18% reduction in the composite of cardiovascular death or worsening heart failure (HR 0.82 to 95% CI 0.73 to 0.92; P<0.001) [10]. When pooled with DAPA-HF in a prespecified meta-analysis, the combined data from nearly 11,000 patients showed consistent benefit regardless of ejection fraction, diabetes status, or background therapy [10].

The 2023 label revision represented a significant commercial and clinical milestone. Heart failure with preserved ejection fraction had long been a therapeutic wasteland. Few drugs had demonstrated benefit in this population before SGLT2 inhibitors. The updated indication allowed cardiologists to prescribe Farxiga for heart failure without needing to determine a specific EF cutoff.

Post-Market Safety Communications: A Chronological Record

The Farxiga safety profile has been shaped by multiple FDA communications since 2014, some specific to dapagliflozin and others applying to the SGLT2 inhibitor class as a whole [11].

December 2015: Diabetic Ketoacidosis (DKA). The FDA issued a Drug Safety Communication warning that SGLT2 inhibitors could cause DKA, sometimes with only modestly elevated blood glucose (euglycemic DKA). The warning was added to the labels of all approved SGLT2 inhibitors, including Farxiga. The FDA's Adverse Event Reporting System (FAERS) had identified 73 cases of DKA in SGLT2 inhibitor users between March 2013 and May 2015 [11].

September 2017: Acute Kidney Injury Update. The FDA strengthened warnings about AKI after reviewing 101 post-market reports of acute kidney injury in patients taking dapagliflozin or canagliflozin. The label was updated to recommend renal function assessment before initiation and periodic monitoring thereafter [12].

August 2018: Fournier's Gangrene (Necrotizing Fasciitis of the Perineum). A rare but serious class-wide warning was added after the FDA identified 55 unique cases of Fournier's gangrene in SGLT2 inhibitor users over a five-year period from 2013 to 2018. Twelve of these cases involved dapagliflozin [13].

2020: Bladder Cancer Language Softened. Following the completion of long-term follow-up studies and analysis of DECLARE-TIMI 58 data, the FDA allowed AstraZeneca to modify the bladder-cancer precaution. The revised label noted that the initial numerical imbalance was not supported by longer-term data and that no causal association had been established [3].

2022: Lower-Limb Amputation Boxed Warning for Class. While the amputation signal was primarily associated with canagliflozin in the CANVAS trial, the FDA had required class-level monitoring. Post-market data and DECLARE results showed no increased amputation risk with dapagliflozin, and Farxiga never carried the boxed amputation warning that appeared on the Invokana label [14].

The Current Farxiga Label: What Prescribers Need to Know

As of 2025, the Farxiga label carries three distinct indications: type 2 diabetes (as adjunct to diet and exercise), heart failure (NYHA II-IV, full EF spectrum), and CKD at risk of progression [9]. The recommended dose is 10 mg once daily for all three indications. A 5 mg starting dose is available but used primarily in clinical scenarios where tolerability is a concern.

Key contraindications include severe hypersensitivity to dapagliflozin and patients on dialysis [9]. The label recommends against initiation when eGFR is below 25 mL/min/1.73 m² for the diabetes indication, but notably does not impose this restriction for the heart failure and CKD indications. This distinction reflects the DAPA-CKD trial's inclusion of patients with eGFR as low as 25 mL/min/1.73 m² and the recognition that renal benefit persists even at lower filtration rates [8].

The Warnings and Precautions section includes DKA, volume depletion, urosepsis and pyelonephritis, hypoglycemia (when combined with insulin or sulfonylureas), necrotizing fasciitis of the perineum, and genital mycotic infections [9]. The 2022 AHA/ACC/HFSA heart failure guideline gives SGLT2 inhibitors a Class I recommendation for all patients with heart failure regardless of EF or diabetes status, citing DAPA-HF and DELIVER among the supporting evidence [15].

Regulatory Context: Farxiga vs. Other SGLT2 Inhibitors

Dapagliflozin's approval trajectory differs meaningfully from its class competitors. Canagliflozin (Invokana) reached the U.S. market first in 2013 but carried the amputation and fracture warnings from CANVAS. Empagliflozin (Jardiance) arrived in 2014 and received a cardiovascular death reduction indication based on EMPA-REG OUTCOME. Dapagliflozin was the first in the class to secure all three major cardiorenal indications (diabetes, heart failure across the full EF range, and CKD) [9].

The competitive positioning was shaped by trial design choices. EMPA-REG OUTCOME enrolled only patients with established cardiovascular disease, which yielded a mortality signal but limited generalizability. DECLARE enrolled a broader population, producing a heart-failure signal rather than a MACE reduction. AstraZeneca's decision to then run DAPA-HF and DAPA-CKD as standalone trials, rather than rely on subgroup data, created a cleaner regulatory path for each indication [4][5][8].

Ertugliflozin (Steglatro) was approved for diabetes in 2017 but the VERTIS-CV outcomes trial failed to show superiority on its primary cardiovascular endpoint, and Merck has not pursued additional indications [16].

Ongoing and Future Regulatory Activity

AstraZeneca has explored dapagliflozin in several additional clinical contexts. The DAPA-MI trial investigated dapagliflozin initiation in patients hospitalized for acute myocardial infarction without diabetes or heart failure. While the full cardiometabolic outcomes data are being evaluated, early results showed favorable effects on a composite cardiometabolic endpoint [17].

Pediatric development for dapagliflozin in type 1 diabetes has not been pursued following the FDA's 2019 rejection of sotagliflozin's combined SGLT1/SGLT2 inhibitor application for type 1 diabetes and the general regulatory caution around SGLT2 inhibitors in this population due to DKA risk. The current Farxiga label does not include any pediatric indications [9].

Post-market surveillance through FDA Sentinel and FAERS continues, with particular attention to DKA rates in hospitalized patients and long-term renal outcomes in real-world CKD populations [11].